Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia
Go back to Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia| ARROWHEAD RESEARCH (NASDAQ: ARWR) | Delayed: 66.48 -1.26 (1.86%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $67.74 | 52 Week High | $8.22 | |||
| Open | $67.83 | 52 Week Low | $3.07 | |||
| Day High | $68.05 | P/E | N/A | |||
| Day Low | $66.36 | EPS | $-1.30 | |||
| Volume | 4,016,379 | |||||
